Novartis' revenue 2007-2024

Published by
Matej Mikulic,
Feb 3, 2025

In 2024, the Swiss pharmaceutical company Novartis AG’s total revenue amounted to 50.3 billion U.S. dollars. This is an increase of nearly five billion U.S. dollars compared to the year before.

Novartis’ revenue by segment

In 2024, Novartis reported revenues totaling over 50 billion U.S. dollars. In 2023, the company spun off its generic drug division, Sandoz, focusing from there on only on branded and innovative products. 

Competitor Sanofi

Another global leader in the world of healthcare and pharmaceuticals is Sanofi, which is based in Paris, France. In 2023, the French company generated over 43 billion euros worth of revenue. That same year, the majority of Sanofi’s revenue was earned through pharmaceuticals (some 38 billion euros), while the consumer health segment generated just over five billion euros.

Novartis AG's total revenue from 2007 to 2024 (in billion U.S. dollars)

© Statista 2025
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

January 2025

Region

Worldwide

Survey time period

2007 to 2024

Supplementary notes

This statistic was assembled from several editions of Novartis' annual report.
* With the 2015 Annual Report, values back to 2011 were restated, as a result of a series of transactions during 2015.
** During this year, eye care division Alcon was spun off and became an own company. Thus, Alcon's revenues are not included.

*** Reduced revenue due to Sandoz spin-off.

Open this statistic in...
French
Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$1,299 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Novartis "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Novartis

Overview

5

Financials

5

Segments

4

Competitors

6

Research and development

4

Outlook

3

Further related statistics

20

Further Content: You might find this interesting as well

Statistics

Topics

RocheGlobal pharmaceutical industryJohnson & JohnsonNovartisMerck & Co.
All features, all contents, at all times: Learn more about our professional solutions.

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$1,299 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.